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Depression anddementia are commonly concurrent and are both associatedwith increasedmortality among older people.However,
little is known about whether home-dwelling patients newly diagnosed with mild dementia coexisting with depressive symptoms
have excess mortality. We conducted a post hoc analysis based on data from the Danish Alzheimer’s Intervention Study of 330
individuals who were diagnosed with mild dementia within the past 12 months. Thirty-four patients were identified with major
depressive symptoms (MD-S) at baseline. During the 3-year follow-up period, 56 patients died, and, among them, 12 were with
MD-S at baseline. Multivariable analysis adjusting for the potential confounders (age, sex, smoking status, alcohol consumption,
education, BMI, household status, MMSE, CCI, QoL-AD, NPIQ, ADSC-ADL, medication, and RCT allocation) showed that
patients withMD-S had a 2.5-fold higher mortality as compared to the patients without or with only few depressive symptoms. Our
result revealed that depression is possibly associated with increasedmortality in patients withmild dementia. Given that depression
is treatable, screening for depression and treatment of depression can be important already in the earliest stage of dementia to reduce
mortality.
1. Introduction
Dementia is a common and devastating chronic neurodegen-
erative disorder among older people [1]. It is characterized
by progressive memory loss, impairments in orientation and
concentration, difficulty in language and executive func-
tions, and deficits in spatial awareness, comprehension, and
judgment, which all have physical, emotional, and financial
impacts on patients and their caregivers [2]. Alzheimer’s
disease (AD) is the most common etiology for dementia,
accounting for 60–80% of all dementia cases [3]. Worldwide,
over 46 million people live with dementia, and this number
is expected to increase to over 132 million by 2050 [4].
Depression is common in people with dementia, occur-
ring with a prevalence ranging between 10% and 62% [5].
Among AD patients, about 50% may experience a depressive
episode at least once during the course of the disease [6].
Apart from other potential determinants, dementia-related
biological, behavioural, and physiological changes may play
a role in the subsequent development of depression [7–9].
Conversely, among other biological mechanisms, depression
triggers the release of stress hormones, and these may cause
hippocampal injury of the brain, which may subsequently
lead to AD and other forms of dementia [10, 11].
Persons suffering from depression or dementia have
increased mortality compared to the general population [12–
15]. A recently published meta-analysis investigating mortal-
ity in mental disorders including 43 studies of depression
showed that the mortality was almost two times higher in
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people with depression as compared to the general pop-
ulation [13]. Similarly, dementia has been associated with
increased mortality from another meta-analysis [16].
Severity and time since disease onset affect mortality in
patients with depression or dementia [17–20]. Previous stud-
ies have suggested that patients with coexisting depression
and severe dementia have higher mortality rate than patients
with less severe cognitive impairment [21, 22]. Other studies
have also indicated that patients with dementia and severe
depression have increased mortality compared to those with
less severe depression [23].
However, previous studies have mainly focused on clin-
ical depression among patients with moderate to severe
dementia residing in nursing homes [24–26]. To date, little
research has been done to investigate mortality among
home-dwelling patients with mild dementia coexisting with
depressive symptoms.
Thanks to advances in diagnosing cognitive disorders
and the increased awareness among the public and health
professionals, patients with various forms of dementia are
increasingly getting diagnosed in the mild stage of the
diseases. Therefore, it is pertinent to gain knowledge of the
factors affecting the outcome of patients with mild dementia.
2. Aim of the Study
The aim of our study was to examine the prevalence of
depressive symptoms among newly diagnosed home-dwell-
ing patients with mild dementia and the effect of depres-
sive symptoms on all-cause mortality of patients with mild
dementia over a three-year follow-up period.
3. Method
This study is a post hoc analysis based on the Danish Alz-
heimer’s Intervention Study (DAISY) data. The main objec-
tive of the DAISY study was to examine the long-term effi-
cacy of an early psychosocial counselling and support pro-
gramme for home-dwelling patients with mild dementia and
their caregivers. Detailed information regarding the DAISY
study design, methodology, and its interventions is published
elsewhere [27].
In brief, 330 newly diagnosed home-dwelling patients
with mild dementia were included in the multicenter, rater-
blinded, randomized DAISY study. Psychosocial interven-
tions including counselling, education, and support were
given to the patients and their caregivers over a period of 12
months. The follow-up period of the DAISY study was three
years.
3.1. The Study Participants. The inclusion criteria for study
participation were as follows: (1) age ≥ 50 years; (2) home-
living patients who were clinically diagnosed with probable
AD, mixed AD with vascular component, or dementia with
Lewy bodies (DLB), within the past 12 months; (3) mild
dementia with Mini-Mental State Examination (MMSE)
score ≥ 20.
The study participants were recruited from the designated
memory clinics in five districts of Denmark. The patients
were referred to these clinics from their local memory clinics,
family doctors, neurologists, geriatrists, or psychiatrists. If
a patient was referred by the latter, then the diagnosis of
dementia had to be confirmed by a specialist in the recruiting
memory clinic.
All patients met the Diagnostic and Statistical Manual
of Mental Disorder (fourth edition, DSM-IV) criteria for
dementia, National Institute of Neurological and Commu-
nicative Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA) cri-
teria for probable AD, or the McKeith criteria for DLB [28–
30]. Patients were classified as mixed AD if they had probable
AD together with vascular changes in cranial CT, which may
contribute to their symptoms.
Patients with severe somatic or psychiatric comorbidities
including impaired vision and/or hearing that would poten-
tially have effects on their cooperation with the intervention
program were ineligible for the study. Patients participating
in other intervention studies and/or living in a nursing home
at baseline were also excluded.
3.2. Depressive Symptoms Assessment. The Cornell Scale for
Depression in Dementia (CSDD) was used to assess the
depressive symptoms of the eligible participants at baseline
[31]. CSDDwas developed byAlexopoulos et al. in 1988. It has
19 items rating the severity of specific depressive symptoms
on a scale from 0 (no problems) to 2 (severe problems). The
total score ranges from 0 to 38, with higher score indicating
more depressive symptoms.
For the present study, based on the interviews with
both patients and their caregivers, the interviewing clinicians
rated the patients’ depressive symptoms using CSDD [32].
A Cornell score of 0–7 indicates a patient without or with
few depressive symptoms, a score of 8–10 indicates moderate
depressive symptoms, and a score of >10 indicates major
depressive symptoms (MD-S) [31].
3.3. Mortality. We obtained all-cause mortality data for the
study population from the Danish Civil Registration System
by using the unique identification (CPR) number assigned to
every resident in Denmark [33].
3.4. Covariates. The patients’ demographic, lifestyle, and
clinical characteristics were obtained at baseline from either
registers or self-reported information.
A patient’s demographic information included, beyond
age and sex, also household status as living alone or not.
We used education as a proxy for socioeconomic status. Our
study population were generally well educated; they all had
high school education; therefore we counted the number of
years of the education on top of the high school education
and grouped the data as short education (<3 years), medium
education (3-4 years), and long education (>4 years).
Lifestyle variables were self-reported including smoking
status (current, ex-smoker, and never smoked) and alcohol
consumption (no alcohol, ≤1 unit/day, 2-3 units/day, and >3
units/day). Body weight and height were also self-reported.
Body mass index (BMI = weight in kilograms divided by the
square of the height in meters, i.e., kg/m2) was computed
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and divided into three groups: normal weight (18.50 ≤ BMI
< 24.99), overweight (25.00 ≤ BMI < 29.99), and obese (BMI
≥ 30.00) based on the World Health Organization standard
of BMI classification [34]. Due to sample size limitation, we
combined the underweight (BMI < 18.50) group with the
normal weight group for the analyses. However, sensitivity
analysis was conducted.
Regarding patients’ clinical characteristics, we assessed
the following aspects:
(1) Mini-Mental State Examination (MMSE) was used
to assess the cognitive status of participants [35].
The score ranges from 0 to 30 with higher scores
indicating a better cognitive performance.TheMMSE
has both validity and reliability for the diagnosis
and longitudinal assessment of dementia. All patients
referred to the designated memory clinic were exam-
ined using MMSE, and a baseline MMSE score of
at least 20 or above (MMSE ≥ 20) was one of the
inclusion criteria for the study participation.
(2) Charlson Comorbidity Index (CCI) is a weighted
index that takes into account the number and the
seriousness of comorbid illnesses which might affect
mortality [36]. More severe diagnoses have higher
weights. For every 10 years of age above 40, 1 point
is added to the risk. For our study, 19 predefined
diagnostic codes were used to identify comorbid
illnesses recorded in the National Hospital Regis-
ter for each patient during the 3 years before the
dementia diagnosis, and CCI was computed based
on the identified comorbidities. The scores were then
grouped into three categories: 0, 1, and 2 or more.
(3) The patient’s awareness of their memory problem
was assessed using the Anosognosia Rating Scale
(Anosognosia), which is a three-point scale measur-
ing the awareness of memory loss as “full awareness,”
“shallow awareness,” and “no awareness” [37].
(4) The Quality of Life Scale for Alzheimer’s Disease
(QoL-AD) contains 13 items and ranges from 13 to 52
with higher scores indicating a better QoL [38]. In our
study, QoL-AD was rated by the primary caregiver of
a patient.
(5) The Alzheimer’s Disease Cooperative Study Activity
of Daily Living Scale (ADSC-ADL) was used to
assess the activities of daily living for the Alzheimer’s
patients [39]. It has 23 items ranging from 0 to 78.
A patient with a higher score indicated a better daily
activities function.
Besides the clinical assessments, the medications for
depression treatment within 12 months before the study
inclusion were self-reported by the patients (yes/no).
3.5. Statistical Analysis. The differences in the patients’ char-
acteristics between the categories of depressive symptoms
were tested using either a Kruskal-Wallis test for continuous
variables or a Pearson chi-square test for categorical variables.
Cox regression models were used to evaluate the excess
mortality in relation to the levels of depression severity
in patients with mild dementia. Hazard ratios (HRs) and
corresponding 95% confidence intervals (95% CIs) were
calculated for all-cause mortality. Both crude and multivari-
able analyses adjusting for the potential confounding factors
(age, sex, smoking, alcohol consumption, education, BMI,
household status, MMSE, CCI, QoL-AD, NPIQ, ADSC-ADL,
medication, and RCT allocation) were performed.
All test results with 𝑝 < 0.05 were considered as sta-
tistically significant. All analyses were performed using SAS
statistical software (version 9.4).
3.6. Ethical Consideration. The DAISY trial was conducted
in accordance with the Helsinki Declaration. According
to the Danish Act on Research Ethics, approval from the
regional ethical committee was not required. However, the
protocol was presented to the regional ethical committee
for Copenhagen and Frederiksberg municipalities, and the
committee reported that no approval was needed (ID Num-
ber (KF) 02-005/04). The Danish Data Protection Agency
approved the DAISY project (ID Number 2003-41-3178), and
the project was registered in the Clinical Trial Database
(ISRCTN74848736). All patients and their primary caregivers
gave their written consent to participate in the trial.
4. Results
4.1.ThePatients’ Baseline Characteristics. Themean age of the
study population was 76.2 years, 151 were males, and 179 were
females (Table 1). The majority of the patients had probable
AD (72.4%), followed bymixed AD (24.9%) and DLB (2.7%).
At the baseline, 34 (10.3%) patients hadMD-S, 54 (16.4%)
had moderate depressive symptoms, and 242 (73.3%) had no
or few depressive symptoms. In the MD-S group, 15 (44.1%)
individuals were treatedwith antidepressants, which is higher
than the group with moderate depressive symptoms (27.8%)
and the group with no or few depressive symptoms (22.7%).
There was no statistically significant difference in sex,
household status, education, smoking status, alcohol con-
sumption, and BMI status between the three graduations of
depressive symptoms. However, clinical assessments includ-
ing CCI, QoL-AD, ADSC-ADL, and NPIQ were significantly
different across these three groups (𝑝 < 0.05) (Table 1).
4.2. All-Cause Mortality at 3-Year Follow-Up. During the 3-
year follow-up period, 56 (17.0%) patients died. Of them, 12
patients had MD-S (including 4 persons treated with antide-
pressants at baseline), 6 had moderate depressive symptoms,
and 38 had no or few depressive symptoms at baseline.
Kaplan-Meier survival curves for the three groups are
presented in Figure 1. Comparison by log-rank test showed
a significant difference in the mortality rate over the follow-
up period only between the MD-S group and the group with
no or few depressive symptoms, that is, the reference group.
Multivariable analysis adjusting for the potential confound-
ers (model 2) showed that patients with MD-S had an almost
2-fold increased mortality compared to the reference group
[HR = 2.13, 95%CI (1.05–4.34), 𝑝 = 0.037]. Further adjusting
for the clinical assessments (model 3) showed an even more
increased all-cause mortality [HR = 2.50, 95% CI (1.03–6.06),
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Table 1: Baseline characteristics of patients with mild dementia stratified by Cornell Scores.
Variables Total(𝑛 = 330) Category
Cornell score
0–7
(𝑛 = 242)
Cornell score
8–10
(𝑛 = 54)
Cornell score
>10
(𝑛 = 34)
Test
(𝑝 value)
Age, median (interquartile
range) 77.1 (9.4) 77.1 (9.1) 75.7 (9.8) 78.6 (12.4) 0.15
Sex 151 Male 112 21 18 0.41
179 Female 130 33 16
Household status 102 Living alone 78 14 10 0.65
228 Living with others 164 40 24
Education
205 Short education(<3 yrs) 151 34 20
0.1090 Medium education(3-4 yrs) 70 14 6
35 Long education(>4 yrs) 21 6 8
Smoking status
95 Never smoked 70 15 10
0.99147 Past smoker 108 25 14
88 Current smoker 64 14 10
Alcohol consumption
26 No alcohol 20 2 4
0.20235 ≤1 unit per day 171 39 25
57 2-3 units per day 45 8 4
12 >3 units per day 6 5 1
BMI
172 Normal 124 29 19
0.41118 Overweight 88 21 9
39 Obese 30 3 6
MMSE, median
(interquartile range) 24.0 (4.0) 24.0 (4.0) 24.0 (5.0) 24.0 (4.0) 0.76
Dementia format
239 Probable AD 175 43 21
0.1282 Mixed AD 62 10 10
9 DLB 5 1 3
CCI
137 0 110 14 13
0.01140 1 90 34 16
53 2 42 6 5
Anosognosia
35 No awareness 28 5 2
0.66196 Shallow awareness 139 36 21
98 Full awareness 75 13 10
Treated with antidepressants
within 12 months
85 Yes 55 15 15 0.02
239 No 183 38 18
QoL-AD, median
(interquartile range) 33.0 (8.0) 35.0 (8.0) 30.0 (7.0) 29.0 (8.0) <0.0001
ADSC-ADL, median
(interquartile range) 64.0 (16.0) 65.0 (16.0) 62.5 (13.0) 61.0 (15.0) 0.04
NPIQ, median (interquartile
range) 3.0 (4.0) 2.0 (3.0) 6.0 (6.0) 7.0 (7.0) <0.0001
Randomisation 163 Control 110 32 21 0.06
167 DAISY intervention 132 22 13
MMSE = Mini-Mental State Examination.
Probable AD = probable Alzheimer’s disease.
Mixed AD = mixed Alzheimer’s disease with vascular component.
DLB = dementia with Lewy bodies.
QoL-AD = Quality of Life Scale for Alzheimer’s Disease.
ADSC-ADL = Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale.
CCI = Charlson Comorbidity Index.
𝑝 values are from a Kruskal-Wallis test (continuous variables) or a Pearson chi-squared test (categorical variables).
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Figure 1: Depressive symptoms and death.
𝑝 = 0.042] during the three-year follow-up period (Table 2).
Both crude andmultivariable analyses showed no statistically
significant increased mortality for patients with moderate
depressive symptoms compared to the patients with few or
none depressive symptoms (Table 2).
The interaction between the depressive symptoms and
dementia severity represented by the MMSE score was
insignificant. The interaction between the depressive symp-
toms and the intervention between the randomized and the
control group was also insignificant. A sensitivity analysis
where the BMI groups were expanded to including an
underweight group (BMI < 18.50) did not change the study
conclusions.
5. Discussion
In this post hoc analysis of 330 home-dwelling patients newly
diagnosed with mild dementia, we found that the patients
with MD-S had significantly higher all-cause mortality com-
pared to the patients without or with few depressive symp-
toms during the three-year follow-up period. The patients
with moderate depressive symptoms did not have increased
all-cause mortality as compared to the reference group.
There is not much evidence of the association between
depressive symptoms and mortality in home-dwelling
patients with dementia and even less evidence for patients
newly diagnosed with mild dementia. Of the existing
studies, differences in the study samples, study design,
follow-up period, potential confounders, and measurement
of depressive symptoms make them difficult to compare.
To the best of our knowledge, the study that is closely
comparable to our study is by Lara et al., a recently published
community-based study among individuals aged ≥ 65 years
exploring the excess mortality due to depressive symptoms.
They found that, among newly diagnosed AD patients (i.e.,
incidence of AD patients during 5.3 years of follow-up),
depressive symptoms (measured in CES-D) were associated
with higher mortality [HR = 1.88, 95% CI (1.12–3.18)] com-
pared to no depressive symptoms [40].
However, neither Lara et al.’s nor our study assessed the
presence of depression based on clinical criteria. Although
44%of patientswithMD-S in our studywere also treatedwith
antidepressants, we do not know whether they had a diag-
nosis of major depression. Furthermore, we cannot identify
whether some patients might have had major depression but
they were treated with antidepressants and therefore might
not present any depressive symptoms at the timewe included.
However, we additionally performed analysis among patients
with antidepressants treatment at baseline, although an
increasedmortality riskwas shown among patients withMD-
S compared to the reference group in model 3, but due to
the sample size limitation, we cannot provide a concrete
conclusion. Among those without antidepressants treatment
at baseline, no significant mortality risk was observed across
different severity of depressive symptoms (data not shown in
this article but are available for request).
Nevertheless, despite the differences in methodologies,
our finding is generally in line with previous studies that
also found high all-cause mortality among individuals with
concurrent depression and dementia [22, 25, 41–43]. A
study conducted by Janzing et al. studying the relationship
between depression and mortality in elderly subjects with
mild dementia living in nursing homes found that individuals
who also had moderate to severe depression (Geriatric
Mental State) were at higher risk of death during 1-year period
than individuals without such depression [OR = 4.31, 95% CI
(1.38–13.46)] [41].
Another recently published cohort study with 676
community-dwelling elderly individuals in rural Greece
showed that people with mild to moderate cognitive impair-
mentwith coexisting severe depression (GeriatricDepression
Scale (GDS) > 10) had increased all-cause mortality [HR =
1.77, 95% CI (1.13–2.78)] during an 8-year period [25].
Notably, the two studies mentioned above had combined
moderate depression with severe depression for themortality
risk estimation. In our study, we used three different cut-
offs to group the severity of depressive symptoms into three
different levels, and we did not find significantly increased
mortality in patients with moderate depressive symptoms
compared to those with no or few depressive symptoms.
Methodological differences in ascertaining depression
severity could play a role. We used an instrument that was
specially developed and validated for people with dementia,
the CSDD, to assess depressive symptoms in our study
population [31]. The instruments used in previous studies,
GDS and GMS, were often used in geriatric research but
not specially developed for patients with dementia. Never-
theless, increased all-cause mortality has been consistently
observed among patients with mild AD/dementia and severe
depression/depressive symptoms compared to those without,
regardless of the instruments used for assessing depression,
speaking in favour of a true association.
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Table 2: The association of depressive symptoms with mortality in patients with mild dementia.
Number of deaths Model 1 𝑝 value Model 2 𝑝 value Model 3 𝑝 value
HR (95% CIs) HR (95% CIs) HR (95% CIs)
No or few depressive symptoms
(Cornell score of 0–7) 38 1 — 1 — 1 —
Moderate depressive symptoms
(Cornell score of 8–10) 6 0.68 (0.29–1.61) 0.384 0.70 (0.28–1.75) 0.446 0.48 (0.17–1.37) 0.172
Major depressive symptoms
(Cornell score of > 10) 12 2.55 (1.33–4.87) 0.005 2.13 (1.05–4.34) 0.037 2.50 (1.03–6.06) 0.042
Model 1: crude analysis without adjustment for potential confounders.
Model 2: multivariable analysis adjusted for age, sex, smoking status, alcohol consumption, education, BMI, household status, MMSE, CCI, and RCT.
Model 3: multivariable analysis adjusted for all the confounders in model 2 and Qol-AD, NPIQ, and ADSC-ADL, treatment with antidepressants within 12
months.
HR = hazard ratio. 95% CIs = 95% confidence intervals.
An large longitudinal study by White et al. (𝑛 = 9560)
found that the duration of depressive symptoms was asso-
ciated with mortality in a dose-response manner, meaning
that the longer the period with depressive symptoms a person
had suffered, the higher the mortality [44]. Although 44%
of the patients in our study with MD-S reported treatment
with antidepressants within the 12months before the baseline
mesurement, we lack further information on how long the
patients had had depressive symptoms prior to baseline, and
therefore we could not confirm the aforementioned findings
of White et al.
The present study used post hoc data from the DAISY
intervention study. It may be argued that the individuals
who underwent the intervention programmes had different
mortality rate from the control group. Out of this concern,
we added the intervention allocation as one of the potential
confounders and adjusted for it in the final model. We
also performed an interaction test and found no significant
interaction between the intervention and the depressive
symptoms for 3-year mortality risk; that is, the depressive
symptom effect is not different between the randomized and
the control group (data not shown in this article but are
available for request).
Although we found that the patients with MD-S had
significantly higher all-cause mortality compared to the
patients without or with few depressive symptoms during the
three-year follow-up period, because of the relatively small
effect size of our study, we cannot be sure that we have not
missed clinically relevant effects, butwe are sure that (with the
usual 5% error = significance level) significant effects are not
chance findings. Nevertheless, besides mortality, depression
indirectly affects the quality of life of the patients and their
families [45, 46] and therefore must be detected and treated
early on among patients with dementia.
Despite the limitations, our study has some advantages.
We carefully adjusted our analyses for possible confounding
through the inclusion of a wide range of indicators repre-
senting socioeconomic status, lifestyle factors, and clinical
characteristics, including indicators of cognitive impairment.
Additionally, we also included comorbidities and the use of
antidepressants.
6. Conclusion
Although the etiology of depression in dementia is probably
multifactorial, the results of our study indicate that patients
with mild dementia due to AD or DLB and concurrent with
MD-S had higher mortality compared to those with no or
few depressive symptoms. It is therefore important to pay
special attention to this particular group of patients, given
that depression can be effectively treated.
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